Allworth Financial LP Has $893,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

Allworth Financial LP lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 55.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,647 shares of the medical research company’s stock after buying an additional 2,361 shares during the period. Allworth Financial LP’s holdings in Agilent Technologies were worth $893,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. AMF Tjanstepension AB bought a new position in Agilent Technologies in the 3rd quarter valued at approximately $2,726,000. Creative Planning raised its stake in shares of Agilent Technologies by 5.9% during the third quarter. Creative Planning now owns 44,910 shares of the medical research company’s stock valued at $6,668,000 after acquiring an additional 2,498 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Agilent Technologies by 9.5% during the third quarter. Sequoia Financial Advisors LLC now owns 31,234 shares of the medical research company’s stock worth $4,638,000 after purchasing an additional 2,720 shares during the period. Weaver Capital Management LLC bought a new stake in shares of Agilent Technologies in the third quarter worth $490,000. Finally, Commerzbank Aktiengesellschaft FI acquired a new stake in Agilent Technologies in the third quarter valued at $271,000.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $137.21 on Thursday. The business has a 50-day simple moving average of $141.13 and a 200 day simple moving average of $139.30. The firm has a market capitalization of $39.15 billion, a price-to-earnings ratio of 31.04, a PEG ratio of 3.65 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. Agilent Technologies, Inc. has a one year low of $124.16 and a one year high of $155.35.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the firm earned $1.38 earnings per share. Agilent Technologies’s revenue for the quarter was up .8% on a year-over-year basis. On average, research analysts anticipate that Agilent Technologies, Inc. will post 5.56 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.72%. Agilent Technologies’s payout ratio is presently 22.40%.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Wall Street Analysts Forecast Growth

Several brokerages have commented on A. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Bank of America reduced their target price on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. JPMorgan Chase & Co. dropped their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Finally, Sanford C. Bernstein dropped their target price on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $144.38.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.